Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice
Van Rhijn BWG, Catto JW, Goebell P, Knuechel R, Shariat SF, Van Der Poel HG, Sanchez-Carbayo M, Thalmann GN, Schmitz-Draeger BJ, Kiemeney LA (2014)
Publication Type: Journal article
Publication year: 2014
Journal
Publisher: Elsevier
Book Volume: 32
Pages Range: 1078-87
Journal Issue: 7
DOI: 10.1016/j.urolonc.2014.07.002
Abstract
To summarize the current status of clinicopathological and molecular markers for the prediction of recurrence or progression or both in non-muscle-invasive and survival in muscle-invasive urothelial bladder cancer, to address the reproducibility of pathology and molecular markers, and to provide directions toward implementation of molecular markers in future clinical decision making.Immunohistochemistry, gene signatures, and FGFR3-based molecular grading were used as molecular examples focussing on prognostics and issues related to robustness of pathological and molecular assays.The role of molecular markers to predict recurrence is limited, as clinical variables are currently more important. The prediction of progression and survival using molecular markers holds considerable promise. Despite a plethora of prognostic (clinical and molecular) marker studies, reproducibility of pathology and molecular assays has been understudied, and lack of reproducibility is probably the main reason that individual prediction of disease outcome is currently not reliable.Molecular markers are promising to predict progression and survival, but not recurrence. However, none of these are used in the daily clinical routine because of reproducibility issues. Future studies should focus on reproducibility of marker assessment and consistency of study results by incorporating scoring systems to reduce heterogeneity of reporting. This may ultimately lead to incorporation of molecular markers in clinical practice.
Authors with CRIS profile
Involved external institutions
Antoni van Leeuwenhoek
Netherlands (NL)
University of Sheffield
United Kingdom (GB)
Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen
Germany (DE)
Medizinische Universität Wien
Austria (AT)
CIC bioGUNE
Spain (ES)
Universität Bern
Switzerland (CH)
Radboud University Nijmegen
Netherlands (NL)
Netherlands (NL)
University of Sheffield
United Kingdom (GB)
Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen
Germany (DE)
Medizinische Universität Wien
Austria (AT)
CIC bioGUNE
Spain (ES)
Universität Bern
Switzerland (CH)
Radboud University Nijmegen
Netherlands (NL)
How to cite
APA:
Van Rhijn, B.W.G., Catto, J.W., Goebell, P., Knuechel, R., Shariat, S.F., Van Der Poel, H.G.,... Kiemeney, L.A. (2014). Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice. Urologic Oncology-Seminars and Original Investigations, 32(7), 1078-87. https://doi.org/10.1016/j.urolonc.2014.07.002
MLA:
Van Rhijn, Bas W. G., et al. "Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practice." Urologic Oncology-Seminars and Original Investigations 32.7 (2014): 1078-87.
BibTeX: Download